First Line Treatments | List of Frontiers open access articles

Original Research

Published on 28 Nov 2025

Cost-effectiveness analysis of eight first-line treatments for metastatic hormone-sensitive prostate cancer in China

in Drugs Outcomes Research and Policies

Zhou Han
Youli Xi
Jian Hu
Ye Wang
Huanyu Ni

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1684966

2,010 views

Original Research

Published on 06 Jun 2022

Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China

in Thoracic Oncology

Haijing Guan
Chunping Wang
Chen Chen
Sheng Han
Zhigang Zhao

Frontiers in Oncology

doi 10.3389/fonc.2022.819674

7,222 views
12 citations

Mini Review

Published on 04 Feb 2026

Does tumor-infiltrating lymphocyte therapy improve survival outcomes in patients with advanced melanoma?

in Gene and Cell Therapy

Piper Ridley-Parish

Frontiers in Medicine

doi 10.3389/fmed.2026.1775031

1,207 views

Case Report

Published on 18 Feb 2025

Hetrombopag treatment for immune thrombocytopenia in pregnancy refractory to corticosteroids and intravenous immunoglobulin: a case report

in Hematology

Luyi Pang
Feng Yu
Xiaoyang Yang

Frontiers in Medicine

doi 10.3389/fmed.2025.1528131

2,860 views
2 citations

Opinion

Published on 06 Feb 2023

Should we reconsider first-line treatments for glaucoma in the setting of meibomian gland dysfunction and ocular surface disease: Glaucoma treatments and its effects

in Inflammatory Eye Diseases

Annie Nguyen

Frontiers in Ophthalmology

doi 10.3389/fopht.2023.958955

2,676 views
1 citation

Original Research

Published on 30 Sep 2025

Cost-effectiveness analysis of first-line treatments for recurrent or metastatic head and neck cancer in China: an economic evaluation based on network meta-analysis

in Pharmacology of Anti-Cancer Drugs

Fen Liu
Yuhang Liu
Guilin Song
Yong Pan
Qiao Xia
Haonan Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1644426

2,929 views

Systematic Review

Published on 17 Sep 2024

Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis

in Cancer Immunity and Immunotherapy

Jingyi Li
Bowen Yang
Zan Teng
Yunpeng Liu
Danni Li
Xiujuan Qu

Frontiers in Immunology

doi 10.3389/fimmu.2024.1430196

13,223 views
11 citations

Original Research

Published on 04 Jan 2023

Comparison of first-line treatments for elderly patients with diffuse large B-cell lymphoma: A systematic review and network meta-analysis

in Cancer Immunity and Immunotherapy

Yangyang Wang
Xiyang Ren
Keke Huang
Xue Liang
Lianfang Pu
Linhui Hu
Zhimin Zhai

Frontiers in Immunology

doi 10.3389/fimmu.2022.1082293

6,259 views
5 citations

Systematic Review

Published on 09 Jun 2025

Efficacy and safety of first-line treatments for recurrent or metastatic nasopharyngeal carcinoma: a systematic review and network meta-analysis

in Cancer Immunity and Immunotherapy

Tongze Cai
Caiyue Lin
Qiongqian Li
Juanmei Mo
Jinghui Zheng
Jianlong Zhou

Frontiers in Immunology

doi 10.3389/fimmu.2025.1485609

5,489 views
1 citation

Systematic Review

Published on 08 Aug 2022

PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis

in Cancer Immunity and Immunotherapy

Xiaoyu Guo
Bowen Yang
Lingzi He
Yiting Sun
Yujia Song
Xiujuan Qu

Frontiers in Immunology

doi 10.3389/fimmu.2022.905651

10,059 views
18 citations

Review

Published on 08 Aug 2022

Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?

in Immunological Tolerance and Regulation

Yue Lv
Huiping Shi
Hong Liu
Lu Zhou

Frontiers in Immunology

doi 10.3389/fimmu.2022.953716

21,069 views
39 citations

Case Report

Published on 29 Sep 2025

Case Report: Prognostic evaluation of immunotherapy in two patients with SMARCA4-UT using TCR as a new marker

in Cancer Immunity and Immunotherapy

Xiayu Wang
Yiwei Zhou
Qijiao Li
Jun Wang
Yu Qian
Bing Yang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1618118

1,848 views

Review

Published on 05 Jul 2023

Cardiovascular toxicity from therapies for light chain amyloidosis

in Cardio-Oncology

Paolo Morfino
Alberto Aimo
Vincenzo Castiglione
Michela Chianca
Giuseppe Vergaro
Carlo Maria Cipolla
Antonella Fedele
Michele Emdin
Iacopo Fabiani
Daniela Cardinale

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2023.1212983

7,180 views
5 citations

Review

Published on 11 Dec 2023

The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy

in Cancer Immunity and Immunotherapy

Xinlin Liu
Junwen Deng
Renshuai Zhang
Jiyao Xing
Yudong Wu
Wujun Chen
Bing Liang
Dongming Xing
Jiazhen Xu
Miao Zhang

Frontiers in Immunology

doi 10.3389/fimmu.2023.1335252

19,000 views
20 citations

Case Report

Published on 13 Aug 2025

Successful sequential treatment with ofatumumab followed by efgartigimod for refractory autoimmune encephalitis with dual anti-NMDAR and anti-GFAP antibody positivity: first case report

in Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders

Xin Tu
Xi Liu
Niao Yang
Dong Sun
Bin Mei
Nao Yan

Frontiers in Immunology

doi 10.3389/fimmu.2025.1640281

3,113 views
1 citation

Original Research

Published on 26 Mar 2025

Potent estrogen receptor β agonists with inhibitory activity in vitro, fail to suppress xenografts of endocrine-resistant cyclin-dependent kinase 4/6 inhibitor-resistant breast cancer cells

in Breast Cancer

Lynn M. Marcho
Christopher C. Coss
Menglin Xu
Jharna Datta
Jasmine M. Manouchehri
Mathew A. Cherian

Frontiers in Oncology

doi 10.3389/fonc.2025.1441896

2,828 views
1 citation

Articles

Cost-effectiveness analysis of eight first-line treatments for metastatic hormone-sensitive prostate cancer in China

Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China

Does tumor-infiltrating lymphocyte therapy improve survival outcomes in patients with advanced melanoma?

Hetrombopag treatment for immune thrombocytopenia in pregnancy refractory to corticosteroids and intravenous immunoglobulin: a case report

Should we reconsider first-line treatments for glaucoma in the setting of meibomian gland dysfunction and ocular surface disease: Glaucoma treatments and its effects

Cost-effectiveness analysis of first-line treatments for recurrent or metastatic head and neck cancer in China: an economic evaluation based on network meta-analysis

Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis

Comparison of first-line treatments for elderly patients with diffuse large B-cell lymphoma: A systematic review and network meta-analysis

Efficacy and safety of first-line treatments for recurrent or metastatic nasopharyngeal carcinoma: a systematic review and network meta-analysis

PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis

Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?

Case Report: Prognostic evaluation of immunotherapy in two patients with SMARCA4-UT using TCR as a new marker

Cardiovascular toxicity from therapies for light chain amyloidosis

The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy

Successful sequential treatment with ofatumumab followed by efgartigimod for refractory autoimmune encephalitis with dual anti-NMDAR and anti-GFAP antibody positivity: first case report

Potent estrogen receptor β agonists with inhibitory activity in vitro, fail to suppress xenografts of endocrine-resistant cyclin-dependent kinase 4/6 inhibitor-resistant breast cancer cells